A

Arcutis Biotherapeutics
D

ARQT

13.020
USD
-0.40
(-2.98%)
مغلق
حجم التداول
80,423
الربح لكل سهم
-1
العائد الربحي
-
P/E
-8
حجم السوق
1,523,920,575
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    R
    RARE
    -1.920
    (-4.31%)
    42.590 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Arcutis Biotherapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.